Vivani Medical Inc VANI
News
Vivani Medical Announces Participation in Upcoming Investor Conferences
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Vivani Medical Withdraws Record Date for Spin Off of Cortigent Subsidiary

